Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 2019-2023, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-781501
ABSTRACT
Abstract Tumor cells avoid immune surveillance by overexpressing ligands of checkpoint receptors on tumor cells or adjacent cells, resulting in inability or exhaustion of T cells. Numerous studies have shown that lymphoma cells highly expressed programmed cell death ligand-1 (PD-L1), suggesting that PD-1 may become an important target for lymphoma treatment. By targeting the PD-1 protein, the cellular activity of T cells will be significantly enhanced, and the tumor growth will be inhibited. Recently, antibodies against PD-1 have shown high efficacy and safety in the clinical studies of lymphoma, which are expected to become the targeted therapeutic drugs for lymphoma. In order to deeply understand the application of PD-1 antibody in treatment of lymphoma, this review briefly summaries the present state of lymphoma studies, the action mechanism and preparation method of PD-1 antibody in clinical treatment of lymphoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Apoptosis
/
B7-H1 Antigen
/
Programmed Cell Death 1 Receptor
/
Lymphoma
/
Antibodies, Monoclonal
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS